Scinai Immunotherapeutics (SCNI) Retained Earnings (2015 - 2026)

Scinai Immunotherapeutics has disclosed Retained Earnings across 12 years of filings, most recently posting -$124.3 million for Q2 2026.

• In Q2 2026, Retained Earnings fell 2.14% year-over-year to -$124.3 million; the TTM figure through Jun 2026 stood at -$124.3 million (down 2.14% YoY), while the FY2025 annual figure was -$125.8 million, down 7.07% from the prior year.
• Retained Earnings came in at -$124.3 million for Q2 2026 at Scinai Immunotherapeutics, down from -$122.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of -$108.2 million in Q3 2022 to a low of -$126.8 million in Q2 2024.
• Average Retained Earnings over 5 years is -$119.7 million, with a median of -$120.8 million recorded in 2023.
• The largest YoY upside for Retained Earnings was 67.94% in 2022 against a maximum downside of 202.44% in 2022.
• Over 5 years, Retained Earnings stood at -$115.8 million in 2022, then fell by 5.61% to -$122.3 million in 2023, then increased by 3.92% to -$117.5 million in 2024, then slipped by 7.07% to -$125.8 million in 2025, then climbed by 1.25% to -$124.3 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were -$124.3 million in Q2 2026, -$122.3 million in Q1 2026, and -$125.8 million in Q4 2025.